Brevan Howard Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Brevan Howard Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.41M	Buy	10,723 +9,242	+624%	+$1.23M	0.01%	724
2025 Q4	$210K	Sell	1,481 -2,403	-62%	-$348K	﹤0.01%	1555
2025 Q3	$545K	Sell	3,884 -11,752	-75%	-$1.59M	﹤0.01%	1251
2025 Q2	$1.97M	Buy	+15,636	New	+$1.79M	0.01%	745
2025 Q1	–	Sell	-6,600	Closed	-$901K	–	1354
2024 Q4	$901K	Buy	6,600 +507	+8%	+$62.7K	0.01%	458
2024 Q3	$702K	Buy	6,093 +2,109	+53%	+$289K	﹤0.01%	578
2024 Q2	$548K	Sell	3,984 -2,146	-35%	-$294K	﹤0.01%	574
2024 Q1	$845K	Buy	6,130 +624	+11%	+$85.2K	0.01%	313
2023 Q4	$725K	Buy	5,506 +3,551	+182%	+$409K	0.01%	347
2023 Q3	$220K	Buy	+1,955	New	+$206K	﹤0.01%	308

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's NBIX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Neurocrine Biosciences (NBIX) stake by 624% in Q1 2026, buying an estimated $1.23M and bringing the position to 10,723 shares worth $1.41M. The position accounts for 0.01% of the portfolio, ranked #724.

Brevan Howard Capital Management first reported a position in NBIX in Q3 2023 and has held it in 10 quarters since. The position peaked at $1.97M in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Brevan Howard Capital Management held 10,723 shares of Neurocrine Biosciences worth $1.41M as of Q1 2026.
Brevan Howard Capital Management bought 9,242 Neurocrine Biosciences shares in Q1 2026, an estimated $1.23M.
Neurocrine Biosciences made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #724 holding.
Brevan Howard Capital Management first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 10 quarters since.
Brevan Howard Capital Management's Neurocrine Biosciences position peaked at $1.97M in Q2 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.